Table 2.
Baseline characteristics of patients with sustained viral suppression over 24 months in the Infectious Diseases. Institute research cohort
| Duration of HAART | 6 months (N = 380) | 12 months (N = 339) | 24 months (N = 309) | ||||||
| Variable | CD4 increase < 50 cells/μl | CD4 increase ≥ 50 cells/μl | P value* | CD4 increase < 100 cells/μl | CD4 increase > 100 cells/μl | P value | CD4 increase < 200 cells/μl | CD4 increase > 200 cells/μl | P value |
| SO-CD4 | 78 (21%) | 302 (79%) | 151 (45%) | 188 (55%) | 166 (54%) | 143 (46%) | |||
| Age (yrs), [median (IQR)] | 38(33–44) | 37(33–43) | 38(33–45) | 37(32–44) | 37(32–44) | 41(34–45) | |||
| ≤ 35 | 30(38%) | 126(42%) | 0.60 | 53(35%) | 84(45%) | 0.14 | 58(35%) | 69(48%) | 0.02 |
| Gender | |||||||||
| Female | 53(68%) | 216(71%) | 0.54 | 108(71%) | 136(72%) | 0.87 | 120(72%) | 107(74%) | 0.62 |
| BMI increase [median (IQR)] | 0.83 (-0.4–2.0) | 1.31 (0–2.56) | 0.49 | 1.4(0.0–2.5) | 2.3(0.7–3.9) | <0.01 | 1.3(0–2.5) | 2.8(0.7–4.6) | 0.86 |
| HAART regimen initiated | |||||||||
| D4T-3TC-EFZ/NVP | 40(14%) | 242(86%) | 94(62%) | 154(82%) | 117(38%) | 110(36%) | 0.62 | ||
| AZT-3TC-EFZ/NVP | 38(39%) | 60(61%) | <0.01 | 57(38%) | 34(18%) | <0.01 | 49(16%) | 33(11%) | |
| Baseline CD4 count [Median(IQR)] | 123(84–186) | 99(29–162) | <0.01 | 122(78–189) | 96(14–162) | <0.01 | 119(77–176) | 87(11–158) | <0.01 |
|
Hepatitis BSAg * (270 tests done) |
|||||||||
| Positive | 8(31%) | 18(69%) | 0.17 | 10(7%) | 11(6%) | 0.93 | 10(6%) | 11(8%) | 0.24 |
| Negative | 59(20%) | 233(80%) | 114(75%) | 145(77%) | 131(79%) | 102(71%) | |||
* NOTE: The analysis was limited to only 270 patients that were tested for Hepatitis B surface antigen sero-status